1. POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

3. Where Do We Stand With NOACs in AF 6 Years Later?

4. Danish Registry for AF – Larsen Analysis: Similar Ischemic Stroke Rates

5. Danish Registry for AF – Larsen Analysis: Any Bleeding

6. Danish Registry for AF – Larsen Analysis: Mortality

7. Danish Registry for AF -- Staerk Analysis: Decreased Ischemic Stroke Rates

8. Danish Registry for AF -- Staerk Analysis: Intracranial Bleeding Rates

9. Danish Registry for AF -- Larsen Analysis: What Did We Learn?

10. First Medicare Analysis: CV, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for NVAF

11. Second Medicare Analysis: Dabigatran and Rivaroxaban -- Demographics

12. Second Medicare Analysis: Dabigatran and Rivaroxaban -- ICH

13. Second Medicare Analysis: Dabigatran vs. Rivaroxaban -- Mortality

14. Danish Registry for AF -- Gorst-Rasmussen Data: Bleeding With Different Doses of Rivaroxaban and Dabigatran

15. Benefit of Comparison With Observational Data

16. Idarucizumab: A Specific Reversal Agent for Anticoagulant Activity of Dabigatran

17. RE-VERSE AD™: Primary Endpoint in Group A & B With Idarucizumab -- dTT and ECT

18. RE-VERSE AD: Study Update

19. RE-VERSE AD: Multicenter, Ongoing, Open-label, Single-arm Phase 3-S

20. RE-VERSE AD: Selected Secondary Endpoints

21. RE-VERSE AD: Updated Patient Demographics

22. RE-VERSE AD -- Group A: Updated Site of Index Bleed

23. RE-VERSE AD -- Group B: Updated Indications for Surgery/Procedures

24. RE-VERSE AD: Updated Primary Results

25. RE-VERSE AD -- Group A: Updated Local Confirmation of Hemostasis

26. RE-VERSE AD -- Group B: Updated Periprocedural Hemostasis

27. RE-VERSE AD -- Updated Adjudicated Post-Reversal Thromboembolic Events Through 90 Days

28. RE-VERSE AD: Updated Reinitiation of Antithrombotic Treatment within 90 days

29. RE-VERSE AD: Updated Mortality (Kaplan-Meier Survival)

30. RE-VERSE AD: Updated Conclusions

31. RE-VERSE AD: Patients Treated With More Than One 5 g Dose of Idarucizumab -- Updated Analysis

32. Andexanet: Reversal of Factor Xa Inhibitor Activity

33. ANNEXA- Phase 3: Andexanet Reverses the Effects of Factor Xa Inhibitors

34. ANNEXA-4: Phase 4 Study With Andexanet

35. Comparison of Features of Idarucizumab and Andexanet

36. Ciraparantag

37. What Affects Choice of Anticoagulant?

38. Abbreviations

39. Abbreviations (cont)